Retired Cholesterol Drug Shows Promise for Alzheimer's Prevention in Small Trial

The DEPEND trial investigated whether probucol, a discontinued cholesterol medication, could boost brain-protective proteins in older adults at risk for Alzheimer's disease. The study focused on increasing apolipoprotein E (apoE) levels in cerebrospinal fluid, as this protein plays a crucial role in brain health and clearing toxic deposits associated with dementia.

This open-label trial enrolled 23 cognitively intact participants over age 55. Since probucol absorption varies significantly between individuals, researchers first developed personalized dosing algorithms to achieve optimal blood concentrations for each participant. This individualized approach aimed to maximize the drug's effectiveness while minimizing potential side effects.

Participants received their customized probucol doses for 12 months while researchers closely monitored cerebrospinal fluid apoE levels and safety parameters. The trial design allowed scientists to assess both short-term dosing optimization and longer-term effects on brain biochemistry. Completed in March 2017, this small but innovative study represents a novel approach to Alzheimer's prevention.

The research highlights the potential for repurposing existing medications for longevity applications. By targeting apoE levels, this strategy could theoretically enhance the brain's natural protective mechanisms before cognitive decline begins. While probucol was withdrawn from many markets due to side effects, careful monitoring and personalized dosing might make it viable for specific preventive applications in high-risk populations seeking proactive brain health optimization.